These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. García F; Plana M; Ortiz GM; Bonhoeffer S; Soriano A; Vidal C; Cruceta A; Arnedo M; Gil C; Pantaleo G; Pumarola T; Gallart T; Nixon DF; Miró JM; Gatell JM AIDS; 2001 Jun; 15(9):F29-40. PubMed ID: 11416735 [TBL] [Abstract][Full Text] [Related]
7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
8. [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results]. Rey D; Schmitt MP; Hess-Kempf G; Krantz V; Partisani M; Bernard-Henry C; Lang JM Pathol Biol (Paris); 2001 Sep; 49(7):559-66. PubMed ID: 11642019 [TBL] [Abstract][Full Text] [Related]
9. Structured treatment interruptions for the management of HIV infection. Lori F; Lisziewicz J JAMA; 2001 Dec; 286(23):2981-7. PubMed ID: 11743839 [TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure. Montroni M; Monforte AD Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591 [TBL] [Abstract][Full Text] [Related]
11. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434 [TBL] [Abstract][Full Text] [Related]
12. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895 [TBL] [Abstract][Full Text] [Related]
13. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420 [TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. Fischl MA AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785 [TBL] [Abstract][Full Text] [Related]
15. Molecular biological assessment methods and understanding the course of the HIV infection. Katzenstein TL APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050 [TBL] [Abstract][Full Text] [Related]
16. Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. Sued O; Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Claramonte X; Plana M; Tuset M; Pumarola T; Gallart T; Gatell JM; Miró JM PLoS One; 2015; 10(7):e0131651. PubMed ID: 26186440 [TBL] [Abstract][Full Text] [Related]
17. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK; MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060 [TBL] [Abstract][Full Text] [Related]
18. [The current status of structured treatment interruption]. Nakata H; Mitsuya H Nihon Rinsho; 2002 Apr; 60(4):807-12. PubMed ID: 11968793 [TBL] [Abstract][Full Text] [Related]
19. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015 [TBL] [Abstract][Full Text] [Related]
20. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. Ruiz L; Ribera E; Bonjoch A; Romeu J; Martinez-Picado J; Paredes R; Díaz M; Marfil S; Negredo E; García-Prado J; Tural C; Sirera G; Clotet B J Infect Dis; 2003 Oct; 188(7):977-85. PubMed ID: 14513417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]